Pulmatrix (PULM) Non-Current Deffered Revenue (2015 - 2023)
Pulmatrix (PULM) posted Non-Current Deffered Revenue of $3.7 million for Q4 2023, down 7.7% sequentially from $4.0 million in Q3 2023, and down 22.71% YoY from $4.8 million in Q4 2022.
Pulmatrix (PULM) Non-Current Deffered Revenue (2015 - 2023) Analysis & Trends
Pulmatrix has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $3.7 million in Q4 2023.
- Quarterly Non-Current Deffered Revenue fell 22.71% year-over-year to $3.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.7 million (down 22.71% YoY) and the FY2023 annual result came in at $3.7 million, down 22.71% from the prior year.
- Non-Current Deffered Revenue declined to $3.7 million in Q4 2023 per PULM's latest filing, from $4.0 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $8.0 million in Q3 2020 and troughed at $3.7 million in Q4 2023.
- A 5-year average of $5.6 million and a median of $5.4 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2019 and 2021: Non-Current Deffered Revenue surged 9558.21% in 2019, then sank 32.14% in 2021.
- Over 5 years, Non-Current Deffered Revenue stood at $7.9 million in 2019, then decreased by 21.72% to $6.2 million in 2020, then fell by 1.61% to $6.1 million in 2021, then declined by 20.55% to $4.8 million in 2022, then dropped by 22.71% to $3.7 million in 2023.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $3.7 million, $4.0 million, and $4.3 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 3.73 Mn |
| Sep 30, 2023 | 4.04 Mn |
| Jun 30, 2023 | 4.35 Mn |
| Mar 31, 2023 | 4.32 Mn |
| Dec 31, 2022 | 4.82 Mn |
| Sep 30, 2022 | 5.08 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Mar 31, 2022 | 5.74 Mn |
| Dec 31, 2021 | 6.07 Mn |
| Sep 30, 2021 | 5.42 Mn |
| Jun 30, 2021 | 5.42 Mn |
| Mar 31, 2021 | 5.81 Mn |
| Dec 31, 2020 | 6.17 Mn |
| Sep 30, 2020 | 7.99 Mn |
| Jun 30, 2020 | 5.37 Mn |
| Mar 31, 2020 | 6.53 Mn |
| Dec 31, 2019 | 7.88 Mn |
| Sep 30, 2019 | 6.47 Mn |
| Jun 30, 2019 | 6.20 Mn |
| Sep 30, 2018 | 67,000.00 |